Phase II BPH will be basis for partnership....as I understand it. This study will enroll quickly...the alternative treatments all have some negative side-effects. There should also be some interest in the upcoming results from the phase Ii localized prostate cancer study. And the PX321 brain cancer drug has fast track and orphan status from the FDA and EMEA. We should expect some news there soon.
The double blinded placebo controlled phase II BPH study should have great results as the IIa study revealed the correct dosing levels.